Burggraaf B, Pouw N, Arroyo SF, et al. - A randomized, double-blind, placebo-controlled, proof-of-concept study was designed to explore whether T2DM is associated with an elevated risk for cardiovascular disease linked to atherogenic dyslipidemia and postprandial hyperlipidemia. Researchers included 12 T2D individuals over the period of 6 weeks. Three biweekly dosages of subcutaneous alirocumab (150 mg) or placebo were receieved by individuals. They assessed fasting and postprandial triglyceride (TG) plasma levels, apolipoprotein (apo) B48, lipoprotein composition isolated by ultracentrifugation, vascular function and markers of inflammation, before and after the intervention. In comparison with placebo, alirocumab treatment decreasing fasting plasma TG levels (between group median change and fasting apo B48 serum levels. The plasma TG area under the curve (AUC) and apo B48 AUC, as well as plasma TG incremental AUC and apo B48 incremental AUC were reduced by alirocumab. It was noted that alirocumab treatment over the 6 weeks period decreased both fasting and postprandial plasma TG levels by reducing the TG levels in VLDL and LDL and the concentration of intestinal remnants.